BILLERICA, Mass. --(BUSINESS WIRE)--Mar. 27, 2026-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection (the “Company”), today announced that the Company’s 2026 annual meeting of shareholders (the “Annual Meeting”) will be held

Reports $43.9 million in revenue and cash balance of $122 million Company expects to achieve cash flow breakeven during 2026 BILLERICA, Mass. --(BUSINESS WIRE)--Mar. 2, 2026-- Quanterix Corporation   (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection,

Collaboration Aims to Expand Access to Early Detection of Potential Disease Marker BILLERICA, Mass. --(BUSINESS WIRE)--Mar. 2, 2026-- Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ: QTRX), today announced a partnership with Life Line Screening (LLS), a national organization focused on

BILLERICA, Mass. --(BUSINESS WIRE)--Feb. 26, 2026-- Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its executive leadership team will participate in the following investor

BILLERICA, Mass. --(BUSINESS WIRE)--Feb. 20, 2026-- Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that it will host a conference call on Monday, March 2, 2026, at 4:30 p.m.

Submission utilizes the comprehensive five-analyte panel and algorithm that formed the basis for Quanterix’s LucentAD® Complete LDT BILLERICA, Mass. --(BUSINESS WIRE)--Feb. 3, 2026-- Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from

Analysis of Subjective Cognitive Decline (SCD) cohort indicates that combining biomarkers representing four key biological axes—amyloid, tau, neurodegeneration, and neuroinflammation—provides a superior window into disease progression at the earliest stages BILLERICA, Mass. --(BUSINESS WIRE)--Jan.

BILLERICA, Mass. --(BUSINESS WIRE)--Jan. 16, 2026-- Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that on January 15, 2026 , inducement grants (the

Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 BILLERICA, Mass. --(BUSINESS WIRE)--Jan. 8, 2026-- Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company transforming healthcare by